Skip to main content
Clinical Trials/JPRN-jRCT1080224091
JPRN-jRCT1080224091
Recruiting
未知

Investigation of the safety and efficacy of Budesonide ( Zentacort Capsules ) in patients with Crohn's disease

ZERIA Pharmaceutical Co., Ltd.0 sites200 target enrollmentOctober 11, 2018
ConditionsCrohn's disease

Overview

Phase
未知
Intervention
Not specified
Conditions
Crohn's disease
Sponsor
ZERIA Pharmaceutical Co., Ltd.
Enrollment
200
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 11, 2018
End Date
TBD
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • mild to moderate active Crohn's disease in patients

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A 12-Week study to find out if the effect of Budesonide/Formoterol SPIROMAX® is at least the same as of SYMBICORT TURBOHALER® and is safe and effective to treat children, teenagers, and adults with asthma.Persistent AsthmaMedDRA version: 14.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2013-000081-11-BETeva Branded Pharmaceutical Products R&D, Inc.671
Active, not recruiting
Not Applicable
A 12-Week study to find out if the effect of Budesonide/Formoterol SPIROMAX® is at least the same as of SYMBICORT TURBOHALER® and is safe and effective to treat children, teenagers, and adults with asthma.Persistent AsthmaMedDRA version: 14.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2013-000081-11-FITeva Branded Pharmaceutical Products R&D, Inc.600
Completed
Phase 3
A 12-Week Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® 160/4.5 mcg Inhalation Powder Versus SYMBICORT® TURBOHALER® 200/6 mcg in Adult and Adolescent Patients with Persistent Asthma.chronical illness of the central nerve systemmultiple sclerosis10029305
NL-OMON38727TEVA Pharma12
Active, not recruiting
Not Applicable
A 12-Week study to find out if the effect of Budesonide/Formoterol SPIROMAX® is at least the same as of SYMBICORT TURBOHALER® and is safe and effective to treat children, teenagers, and adults with asthma.Persistent AsthmaMedDRA version: 16.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2013-000081-11-DKTeva Branded Pharmaceutical Products R&D, Inc.600
Active, not recruiting
Not Applicable
A 12-Week study to find out if the effect of Budesonide/Formoterol SPIROMAX® is at least the same as of SYMBICORT TURBOHALER® and is safe and effective to treat children, teenagers, and adults with asthma.
EUCTR2013-000081-11-ITTeva Branded Pharmaceutical Products R&D, Inc.600